The potential application of ribozymes for the treatment of hematological disorders

Journal of Leukocyte Biology

Volumn 66, Issue 3, 1999, Pages 361-368

  James, Helen A ^a  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

Gene therapy leukemia; HIV I

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGODEOXYNUCLEOTIDE; CD34 ANTIGEN; CD8 ANTIGEN; DNA; ENDONUCLEASE; EXONUCLEASE; FORMIVIRSEN; GENE PRODUCT; MAFOSFAMIDE; MESSENGER RNA; OBLIMERSEN; PROTEIN BCL 2; RETINOIC ACID; RIBOZYME; RNA; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE MYELOBLASTIC LEUKEMIA; BASE PAIRING; CLINICAL TRIAL; DRUG RESISTANCE; ENZYME ACTIVITY; GENE; GENE EXPRESSION; HEMATOLOGIC DISEASE; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; REVIEW; VIRUS INFECTION; VIRUS REPLICATION;

EID: 0032869728     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: 10.1002/jlb.66.3.361     Document Type: Review

References (125)

1. Zamecnik, P. C., Stephenson, M. L. (1978) Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc. Natl. Acad. Sci. USA 75, 280-284.
2. Izant, J. G., Weintraub, H. (1985) Constitutive and conditional suppression of exogenous and endogenous genes by anti-sense RNA. Science 229, 345-352.
3. Rossi, J. J., Cantin, E. M., Sarver, N., Chang, P. F. (1991) The potential use of catalytic RNAs in therapy of HIV infection and other diseases. Pharmacol. Ther. 50, 245-254.
4. Sullenger, B. A., Cech, T. R. (1994) Ribozyme-mediated repair of defective mRNA by targeted trans-splicing. Nature 371, 619-622.
5. James, H. A., Turner, P. C. (1995) Ribozymes. Essays Biochem. 29, 175-192.
6. Cech, T. R., Zaug, A. J., Grabowski, P. J. (1981) In vitro splicing of the ribosomal RNA precursor of Tetrahymena: involvement of a guanosine nucleotide in the excision of the intervening sequence. Cell 27, 487-496.
7. Kruger, K., Grabowski, P. J., Zaug, A. J., Sands, J., Gottschling, D. E., Cech, T. R. (1982) Self-splicing RNA: autoexcision and autocyclization of the ribosomal RNA intervening sequence of Tetrahymena. Cell 31, 147-157.
8. Peebles, C. L., Perlman, P. S., Mecklenburg, K. L., Petrillo, M. L., Yabor, J. H., Jarrell, K. A., Cheng, H.-L. (1986) A self-splicing RNA excises an intron lariat. Cell 44, 213-223.
9. Jones, J. T., Lee, S.-W., Sullenger, B. A. (1996) Tagging ribozyme reaction sites to follow trans-splicing in mammalian cells. Nature Med. 2, 643-648.
10. Darr, S. C., Brown, J. W., Pace, N. R. (1992) The varieties of ribonuclease P. Trends Biol. Sci. 17, 178-182.
11. Guerrier-Takada, C., Gardiner, K., Marsh, T., Pace, N., Altman, S. (1983) The RNA moiety of ribonuclease P is the catalytic subunit of the enzyme. Cell 35, 849-857.
12. Hutchins, C. J., Rathjen, P. D., Forster, A. C., Symons, R. H. (1986) Self-cleavage of plus and minus RNA transcripts of avocado sunblotch viroid. Nucleic Acids Res. 14, 3627-3640.
13. Hernandez, C., Flores, R. (1992) Plus and minus RNAs of peach latent mosaic viroid self-cleave in vitro via hammerhead structures. Proc. Natl. Acad. Sci. USA 89, 3711-3715.
14. Beaudry, D., Bussiere, F., Lareau, F., Lessard, C., Perreault, J.-P. (1995) The RNA of both polarities of the peach latent mosaic viroid self-cleaves in vitro by single hammerhead structures. Nucleic Acids Res. 23, 745-752.
15. Robertson, H. D., Rosen, D. L., Branch, A. D. (1985) Cell-free synthesis and processing of an infectious dimeric transcript of potato spindle tuber viroid RNA. Virology 142, 441-447.
16. Miller, W. A., Hercus, T., Waterhouse, P. M., Gerlach, W. L. (1991) A satellite RNA of barley yellow dwarf virus contains a novel hammerhead structure in the self-cleavage domain. Virology 183, 711-720.
17. Buzayan, J. M., Gerlach, W. L., Bruening, G. (1986) Non-enzymatic cleavage and ligation of RNAs complementary to a plant virus satellite RNA. Nature 323, 349-353.
18. Prody, G. A., Bakos, J. T., Buzayan, J. M., Schneider, I. R., Bruening, G. (1986) Autolytic processing of dimeric plant virus satellite RNA. Science 231, 1577-1580.
19. Forster, A. C., Symons, R. H. (1987) Self-cleavage of plus and minus RNAs of a virusoid and a structural model for the active sites. Cell 49, 211-220.
20. Davies, C., Haseloff, J., Symons, R. H. (1990) Structure, self-cleavage and replication of two viroid-like satellite RNAs (virusoids) of subterranean clover mottle virus. Virology 177, 216-224.
21. Epstein, L. M., Gall, J. G. (1987) Self-cleaving transcripts of satellite DNA from the newt. Cell 48, 535-543.
22. Saville, B. J., Collins, R. A. (1990) A site-specific self-cleavage reaction performed by a novel RNA in Neurospora mitochondria. Cell 61, 685-696.
23. Collins, R. A., Olive, J. E. (1993) Reaction conditions and kinetics of self-cleavage of a ribozyme derived from Neurospora VS RNA. Biochemistry 32, 2795-2799.
24. Beattie T. L., Olive, J. E., Collins, R. A. (1995) A secondary-structure model for the self-cleaving region of Neurospora VS RNA. Proc. Natl. Acad. Sci. USA 92, 4686-4690.
25. Rastogi, T., Beattie, T. L., Olive, J. E., Collins, R. A. (1996) A long-range pseudoknot is required for activity of the Neurospora VS ribozyme. EMBO J. 15, 2820-2825.
26. Wu, H.-N., Lin, Y.-J., Lin, F.-P., Makino, S., Chang, M.-F., Lai, M. M. C. (1989) Human hepatitis δ virus RNA subfragments contain an autocleavage activity. Proc. Natl. Acad. Sci. USA 86, 1831-1835.
27. Perrotta, A. T., Been, M. D. (1991) A pseudoknot-like structure required for efficient self-cleavage of hepatitis delta virus RNA. Nature 350, 434-436.
28. Wu, H.-N., Wang, Y.-J., Hung, C-F., Lee, H.-J., Lai, M. M. C. (1992) Sequence and structure of the catalytic RNA of hepatitis delta virus genomic RNA. J. Mol. Biol. 223, 233-245.
29. Hertel, K. J., Herschlag, D., Uhlenbeck, O. C. (1994) A kinetic and thermodynamic framework for the hammerhead ribozyme reaction. Biochemistry 33, 3374-3385.
30. Hertel, K. J., Uhlenbeck, O. C. (1995) The internal equilibrium of the hammerhead ribozyme reaction. Biochemistry 34, 1744-1749.
31. Sigurdsson, S. T., Eckstein, F. (1995) Structure-function relationships of hammerhead ribozymes: from understanding to applications. Trends Biotech. 13, 286-289.
32. Haseloff, J., Gerlach, W. L. (1988) Simple RNA enzymes with new and highly specific endoribonuclease activities. Nature 33, 585-591.
33. Berzal-Herranz, A., Joseph, S., Chowrira, B. M., Butcher, S. E., Burke, J. M. (1993) Essential nucleotide sequences and secondary structure elements of the hairpin ribozyme. EMBO J. 12, 2567-2574.
34. Pley, H. W., Flaherty, K. M., McKay, D. B. (1994) Three-dimensional structure of a hammerhead ribozyme. Nature 372, 68-74.
35. Scott, W. G., Finch, J. T., Klug, A. (1995) The crystal structure of an all-RNA hammerhead ribozyme: a proposed mechanism for RNA catalytic cleavage. Cell 81, 991-1002.
36. Tuschl, T., Gohlke, C., Jovin, T. M., Westhof, E., Eckstein, F. (1994) A three-dimensional model for the hammerhead ribozyme based on fluorescence measurements. Science 266, 785-789.
37. Marwick, C. (1998) First 'antisense' drug will treat CMV retinitis. J. Am. Med. Assoc. 280, 871.
38. Christoffersen, R. E., Marr, J. J. (1995) Ribozymes as human therapeutic agents. J. Med. Chem. 38, 2023-2037.
39. Homann, M., Tzortzakaki, S., Ritter, K., Sczakiel, G., Tabler, M. (1993) Incorporation of the catalytic domain of a hammerhead ribozyme into antisense RNA enhances its inhibitory effect on the replication of human immunodeficiency virus type I. Nucleic Acids Res. 21, 2809-2814.
40. Kijima, H., Ishida, H., Ohkawa, T., Kashani-Sabet, M., Scanlon, K. J. (1995) Therapeutic applications of ribozymes. Pharmacol. Ther. 68, 247-267.
41. Cantor, G. H., Stone, D. M., McElwain, T. F., Palmer, G. H. (1996) Comparison of the antiviral efficacy of ribozymes and antisense. Antisense Nucleic Acid Drug Dev. 6, 301-304.
42. Lo, K. M. S., Biasolo, M. A., Dehni, G., Palu, G., Haseltine, W. A (1992) Inhibition of replication of HIV-1 by retroviral vectors expressing tat-antisense and anti-tat ribozyme RNA. Virology 190, 176-183.
43. Kobayashi, H., Dorai, T., Holland, J. F., Ohnuma, T. (1994) Reversal of drug sensitivity in multidrug-resistant tumor cells by an MDR1 (PGY1) ribozyme. Cancer Res. 54, 1271-1275.
44. Matsushita, H., Kizaki, M., Kobayashi, H., Ueno, H., Muto, A., Takayama, N., Awaya, N., Kinjo, K., Hattori, V., Ikeda, Y. (1998) Restoration of retinoid sensitivity by MDR1 ribozymes in retinoic acid-resistant myeloid leukemic cells. Blood 91, 2452-2458.
45. Huang, M. E., Ye, Y. C., Chen, S. R., Chai, J. R., Lu, J. X., Zhoa, L., Gu, H. T., Wang, Z. Y. (1988) Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72, 567-572.
46. Castaigne, S., Chomienne, C., Daniel, M. T., Ballerini, P., Berger, R., Fenaux, P., Degos, L. (1990) All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. 1. Clinical results. Blood 76, 1704-1709.
47. Warrell, R. P., Jr., Frankel, S. R., Miller, W. H., Scheinberg, D. A., Itri, L. M., Hittelman, W. N., Vyas, R., Andreeff, M., Tafuri, A., Jakubowski, A., Gabrilove, J., Gordon, M. S., Dmitrovsky, E. (1991) Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N. Engl. J. Med. 324, 1385-1393.
48. Kanamaru, A., Takemoto, Y., Tanimoto, M., Murakami, H., Asou, N., Kobayashi, T., Kuriyama, K., Ohmoto, E., Sakamaki, H., Tsubaki, K., Hiraoka, A., Yamada, O, Oh, H., Saito, K., Matsuda, S., Minato, K., Ueda, T., Ohno, R. (1995) All-trans-retinoic acid for the treatment of newly-diagnosed acute promyelocytic leukemia. Blood 85, 1202-1206.
49. Warrell, R. P., Jr., de The, H., Wang, Z. Y., Degos, L. (1993) Acute promyelocytic leukemia. N. Engl. J. Med. 329, 177-189.
50. de The, H., Lavau, C., Marchio, A., Chomienne, C., Degos, L., Dejean, A. (1991) The PML-RARα fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 66, 675-684.
51. Nason-Burchenal, K., Allopenna, J., Begue, A., Stehelin, D., Dmitrovsky, E., Martin, P. (1998) Targeting of PML/RAR alpha is lethal to retinoic acid-resistant promyelocytic leukemia cells. Blood 92, 1758-1767.
52. Nason-Burchenal, K., Takle, G., Pace, U., Flynn, S., Allopenna, J., Martin, P., George, S. T., Goldberg, A. R., Dmitrovsky, E. (1998) Targeting the PML/RAR alpha translocation product triggers apoptosis in promyelocytic leukemia cells. Oncogene 17, 1759-1768.
53. Lange, W., Cantin, E. M., Finke, J., Dolken, G. (1993) In vitro and in vivo effects of synthetic ribozymes targeted against BCR/ABL mRNA. Leukemia 7, 1786-1794.
54. Snyder, D. S., Wu, Y., Wang, J. L., Rossi, J. J., Swiderski, P., Kaplan, B. E., Forman, S. J. (1993) Ribozyme-mediated inhibition of bcr-abl gene expression in a Philadelphia chromosome-positive cell line. Blood 82, 600-605.
55. Leopold, L. H., Shore, S. K, Newkirk, T. A., Reddy, R. M. V., Reddy, E. P. (1995) Multi-unit ribozyme-mediated cleavage of bcr-abl mRNA in myeloid leukemias. Blood 85, 2162-2170.
56. Mills, K. I., Walsh, V., Gilkes, A. F., Goringe, A., Twomey, C., James, H. A., Gibson, I. (1996) In vitro ribozyme treatment of 32D cells expressing a BCR-ABL construct prolongs the survival of SCID mice. Blood 88, 2296 (abstr.).
57. bcr/abl gene of the Philadelphia chromosome. Science 247, 824-830.
58. Bhatia, R., Verfaillie, C. M., Miller, J. S., McGlave, P. B. (1997) Autologous transplantation therapy for chronic myelogenous leukemia. Blood 89, 2623-2634.
59. Shore, S. K., Nabissa, P. M., Reddy, E. P. (1993) Ribozyme-mediated cleavage of the bcr-abl oncogene transcript: In vitro cleavage of RNA and in vivo loss of p210 protein kinase activity. Oncogene 8, 3183-3188.
60. Liu, J.-H., Cheng, S.-C., Lin, U.-C., Chen, P.-M. (1997) Suppression of the growth of chronic myeloid leukemia by retrovirally transduced mono- and multi-unit ribozymes. Blood 90 (S1), 3601.
61. Mendoza-Maldenado, R., Zentilin, L., Fanin, R., Giacca, M. (1997) Purging of chronic myelogenous leukemia cells by retrovirally-expressed anti-bcr/abl ribozymes. Blood 90 (S1), 2471.
62. James, H., Mills, K., Gibson, I. (1996) Investigating and improving the specificity of ribozymes directed against the bcr-abl translocation. Leukemia 10, 1054-1064.
63. Kuwabara, T., Warashina, M., Tanabe, T., Tani, K., Asano, S., Taira, K. (1997) Comparison of the specificities and activities of hammerhead ribozymes and DNA enzymes with respect to the cleavage of BCR-ABL chimeric L6 (b2a2) mRNA. Nucleic Acids Res. 25 3074-3081.
64. Lange, W., Daskalakis, M., Finke. J., Dolken, G. (1994) Comparison of different ribozymes for efficient and specific cleavage of BCR/ABL related mRNAs. FEBS Lett. 338, 175-178.
65. Wright, L., Wilson, S. B., Milliken, S., Biggs, J., Kearney, P. (1993) Ribozyme-mediated cleavage of the bcr/abl transcript expressed in chronic myeloid leukemia. Exp. Hematol. 21, 1714-1718.
66. Wright, L. A., Milliken, S., Biggs, J. C., Kearney, P. (1998) Ex vivo effects associated with the expression of a bcr-abl-specific ribozyme in a CML cell line. Antisense Nucleic Acid Drug Dev. 8, 15-23.
67. Szczylik, C., Skorski, T., Nicolaides, N. C., Manzella, L., Malaguarnera, L., Venturelli, D., Gewirtz, A. M., Calahretta, B. (1991) Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligonucleotides. Science 253, 562-565.
68. Skorski, T., Nieborowska-Skorska, M., Nicolaides, N. C., Szczylik, C., Iversen, P., Iozzo, R. V., Zon, G., Calabretta, B. (1994) Suppression of Philadelphia-leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotides. Proc. Natl. Acad. Sci. USA 91, 4504-4508.
69. Smetsers, T. F. C. M., van de Locht, L. T. F., Pennings, A. H. M., Wessels, H. M. C., de Witte, T. M., Mensink, E. J. B. M. (1995) Phosphorothioate BCR-ABL antisense oligonucleotides induce cell death, but fail to reduce cellular Bcr-Abl protein levels. Leukemia 9, 118-130.
70. Mahon, F. X., Ripoche, J., Pigeonnier, V., Jazwiec, B., Pigneux, A., Moreau, J. F., Reiffers, J. (1995) Inhibition of chronic myelogenous leukemia cells harboring a BCR-ABL B3A2 junction by antisense oligonucleotides targeted at the B2A2 junction. Exp. Hematol. 23, 1608-1611.
71. de Fabritiis, P., Amadori, S., Petti, M. C., Mancini, M., Montefusco, E., Picardi, A., Geiser, T., Campbell, K., Calabretta, B., Mandelli, F. (1995) In vitro purging with BCR-ABL antisense oligodeoxynucleotides does not prevent haematologic reconstitution after autologous bone marrow transplant. Leukemia 9, 662-664.
72. Luger, S. M., Ratjczak, M. Z., Stadtmauer, E. A., Mangan, P., Magee, D., Silberstein, L., Edelstein, M., Nowell, P., Gewirtz, A. M. (1994) Autografting for chronic myelogenous leukemia with c-myb antisense oligonucleotide purged bone marrow: a preliminary report. Blood 84 (Suppl. 1), 151a (abstr.).
73. Matsushita, H., Kobayashi, H., Mori, S., Kizaki, M., Ikeda, Y. (1995) Ribozymes cleave the AML1/MTG8 fusion transcript and inhibit proliferation of leukemic cells with t(8-21). Biochem. Biophys. Res. Commun. 215, 431-437.
74. Kozu, T., Sueoka, E., Okabe, S., Sueoka, N., Komori, A., Fujiki, H. (1996) In vitro catalytic activities of DNA/RNA chimeric hammerhead ribozymes against AML1-MTG8 mRNA, a fused gene transcript in acute myeloid leukemia with t(8;21). Biochimie 78, 1067-1073.
75. Cai, D. W., Mukhopadhyay, T., Roth, J. A. (1995) Suppression of lung-cancer cell-growth by ribozyme-mediated modification of p53 pre-messenger-RNA. Cancer Gene Ther. 2, 199-205.
76. Kashani-Sabet, M., Funato, T., Florenes, V. A., Fodstad, O., Scanlon, K. J. (1994) Suppression of the neoplastic phenotype in vivo by an anti-ras ribozyme. Cancer Res. 54, 900-902.
77. Kitajima, I., Hanyu, N., Soejima, Y., Hirano, R., Arahira, S., Yamaoka, S., Yamada, R., Maruyama, I., Kaneda, Y. (1997) Efficient transfer of synthetic ribozymes into cells using hemagglutinating virus of Japan (HVJ)-cationic liposomes. Application for ribozymes that target human T-cell leukemia virus type I tax/rex mRNA. J. Biol. Chem. 272, 27099-27106.
78. Yoshida, M., Miyoshi, I., Hinuma, Y. (1982) Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc. Natl. Acad. Sci. USA 79, 2031-2035.
79. Kitajima, I., Shinohara, T., Minor, T., Bibbs, L., Bilakovics, J., Nerenberg, M. (1992) Human T-cell leukemia virus type I tax transformation is associated with increased uptake of oligodeoxynucleotides in vitro and in vivo. J. Biol. Chem. 267, 25881-25888.
80. Beck, J., Nassal, M. (1995) Efficient hammerhead ribozyme-mediated cleavage of the structured hepatitis B virus encapsidation signal in vitro and in cell extracts, but not in intact cells. Nucleic Acids Res. 23, 4954-4962.
81. Welch, P. J., Tritz, R., Yei, S., Leavitt, M., Yu, M., Barber, J. (1996) A potential therapeutic application of hairpin ribozymes: in vitro and in vivo studies of gene therapy for hepatitis C virus infection. Gene Ther. 3, 994-1001.
82. Lieber, A., He, C. Y., Polyak, S. J., Gretch, D. R., Barr, D., Kay, M. A. (1996) Elimination of hepatitis C virus RNA in infected human hepatocytes by adenovirus-mediated expression of ribozymes. J. Virol. 70, 8782-8791.
83. Sakamoto, N., Wu, C. H., Wu, G. Y. (1996) Intracellular cleavage of hepatitis C virus RNA and inhibition of viral protein translation by hammerhead ribozymes. J. Clin. Invest. 98, 2720-2728.
84. Tang, X. B., Hobom, G., Luo, D. (1994) Ribozyme mediated destruction of influenza A virus in vitro and in vivo. J. Med. Virol. 42, 385-395.
85. Zhou, C., Bahner, I. C., Larson, G. P., Zaia, J. A., Rossi, J. J., Kohn, D. B. (1994) Inhibition of HIV-1 in human T-lymphocytes by retrovirally transduced anti-tat and rev hammerhead ribozymes. Gene 149, 33-39.
86. Bauer, G., Valdez, P., Kearns, K., Bahner, I., Wen, S. F., Zaia, J. A., Kohn, D. B. (1997) Inhibition of human immunodeficiency virus-1 (HIV-1) replication after transduction of granulocyte colony-stimulating factor-mobilized CD34(+) cells from HIV-1-infected donors using retroviral vectors containing anti-HIV-1 genes. Blood 89, 2259-2267.
87. + lymphocyte-derived cell lines conferred by using retroviral vectors expressing an HIV-1 RNA-specific ribozyme. J. Virol. 65, 5531-5534.
88. Yamada, O., Yu, M., Yee, J.-K., Kraus, G., Looney, D., Wong-Staal, F. (1994) Intracellular immunization of human T cells with a hairpin ribozyme against human immunodeficiency virus type I. Gene Ther. 1, 38-45.
89. Ojwang, J. O., Hampel, A., Looney, D. J., Wong-Staal, F., Rappaport, J. (1992) Inhibition of human immunodeficiency virus type I expression by a hairpin ribozyme. Proc. Natl. Acad. Sci. USA 89, 10802-10806.
90. Yu, M., Ojwang, J. O., Yamada, O. Hampel, A., Rappaport, J., Looney, D. J., Wong-Staal, F. (1993) A hairpin ribozyme inhibits expression of diverse strains of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 90, 6340-6344.
91. Yamada, O., Leavitt, C., Yu, M., Kraus, G., Wong-Staal, F. (1994) Activity and cleavage site specificity of an anti-HIV-1 ribozyme in human T cells. Virology 205, 121-126.
92. Yu, M., Poeschla, E. M., Yamada, O., De Grandis, P., Leavitt, M. C., Heusch, M., Yee, J.-K., Wong-Staal, F., Hampel, A. (1995) In vitro and in vivo characterization of a second functional hairpin ribozyme against HIV-1. Virology 206, 381-386.
93. Leavitt, M. C., Yu, M., Wong-Staal, F., Looney, D. J. (1996) Ex vivo transduction and expansion of CD4+ lymphocytes from HIV+ donors: prelude to a ribozyme gene therapy trial. Gene Ther. 3, 599-606.
94. Yu, M., Leavitt, M., Maruyama, M., Yamada, O., Young, D., Ho, A., Wong-Staal, F. (1995) Intracellular immunization of human hematopoietic stem/progenitor cells with a ribozyme against HIV-1. Proc. Natl. Acad. Sci. USA 92, 699-703.
95. Wong-Staal, F., Poeschla, E., Looney, D., Yu, M., Leavitt, M., Yamada, O., Yee, J.-K. (1993) RAC Submission #9309-057.
96. Wong-Staal, F., Poeschla, E. M., Looney, D. J. (1998) A controlled, phase 1 clinical trial to evaluate the safety and effects in HIV-1 infected humans of autologous lymphocytes transduced with a ribozyme that cleaves HIV-1 RNA. Human Gene Ther. 9, 2407-2425.
97. Sioud, M. (1996) Ribozyme modulation of lipopolysaccharide-induced tumor necrosis factor-α production by peritoneal cells in vitro and in vivo. Eur. J. Immunol. 26, 1026-1031.
98. Scheid, S., Heinzinger, M., Waller, C. F., Lange, W. (1998) Bcl-2 mRNA-targeted ribozymes: effects on programmed cell death in chronic myelogenous leukemia cell lines. Ann. Hematol. 76, 117-125.
99. Cotter, F., Webb, A., Cunningham, D., Fennell, D., Corbo, M., Ross, P., Walters, J., Judson, L. Raynaud, F., Clarke, P., Dziewanowska, Z. E. (1997) Activity of BCL-2 antisense molecule G3139 against, lymphoma/ leukemia: results from a phase I/IIA clinical trial and further developments. Blood 90 (S1), 2289.
100. Skorski, T., Nieberowska-Skorska, M., Barletta, C., Malaguarnera, L., Szczylik, C., Chen, S. T., Lange, B., Calabretta, B. (1993) Highly efficient elimination of Philadelphia leukemic cells by exposure to bcr/abl antisense oligodeoxynucleotides combined with mafosfamide. J. Clin. Invest. 92, 194-202.
101. Stull, R. A., Zon, G., Szoka, F. C. (1993) Single-stranded phosphodiester and phosphorothioate oligonucleotides bind actinomycin D and interfere with tumor necrosis factor-induced lysis in the L929 cytotoxicity assay. Antisense Res. Dev. 3, 295-300.
102. Blagosklonny, M. V., Neckers, L. M. (1994) Oligonucleotides protect cells from the cytotoxicity of several anti-cancer chemotherapeutic drugs. Anti-Cancer Drugs 5, 437-442.
103. Stein, C. A., Krieg, A. (1994) Problems in the interpretation of data derived from the in vitro and in vivo use of antisense oligodeoxynucleotides. Antisense Res. Dev. 4, 67-69.
104. Crooke, S. T. (1998) An overview of progress in antisense therapeutics. Antisense Nucleic Acids Drug Dev. 8, 115-122.
105. Desjardins, J. P., Sproat, B. S., Beijer, B., Blaschke, M., Dunkel, M., Gerdes, W., Ludwig, J., Reither, V., Rupp, T., Iversen, P. L. (1996) Pharmacokinetics of a synthetic, chemically modified hammerhead ribozyme against the rat cytochrome P-450 3A2 mRNA after single intravenous injections. J. Pharmacol. Exp. Ther. 278, 1419-1427.
106. Miyao, T., Takakura, Y., Akiyama, T., Yoneda, F., Sezak, H., Hashida, M. (1995) Stability and pharmacokinetic characteristics of oligonucleotides modified at terminal linkages in mice. Antisense Res. Dev. 5, 115-121.
107. Sands, H., Gorey-Feret, L. J., Ho, S. P., Bao, Y. J., Cocuzza, A. J., Chidester, D., Hobbs, F. W. (1995) Biodistribution and metabolism of internally H-3 labeled oligonucleotides. II. 3′,5-blocked oligonucleotides. Mol. Pharmacol. 47, 636-646.
108. Pieken, W. A., Olsen, D. B., Benseler, F., Aurup, H., Eckstein, F. (1991) Kinetic characterization of ribonuclease-resistant 2′-modified hammerhead ribozymes. Science 253 314-317.
109. Lyngstadaas, S. P., Risnes, S., Sproat, B. S., Thrane, P. S., Prydz, H. P. (1995) A synthetic, chemically modified ribozyme eliminates amelogenin, the major translation product in developing mouse enamel in vivo. EMBO J. 14, 5224-5229.
110. Paolella, G., Sproat, B. S., Lamond, A. I. (1992) Nuclease resistant ribozymes with high catalytic activity. EMBO J. 11, 1913-1919.
111. Crooke, R. M., Graham, M. J., Cooke, M. E., Crooke, S. T. (1995) In vitro pharmacokinetics of phosphorothioate antisense oligonucleotides. J. Pharmacol. Exp. Ther. 275, 462-473.
112. Bennett, C. F., Chiang, M.-Y., Chan, H., Grimm, S. (1993) Use of cationic lipids to enhance the biological activity of antisense oligonucleotides. J. Liposome Res. 3, 85-102.
113. Giles, R. V., Spiller, D. G., Tidd, D. M. (1995) Detection of ribonuclease H-generated mRNA fragments in human leukemia cells following reversible membrane permeabilization in the presence of antisense oligodeoxynucleotides. Antisense Res. Dev. 5, 23-31.
114. Karlsson, S. (1997) Gene therapy of haematopoietic cells. J. Intern. Med. 242 (Suppl. 740), 95-99.
115. Bertrand, E., Castanotto, D., Zhou, C., Carbonnelle, C., Lee, N. S., Good, P., Chatterjee, S., Grange, T., Pictet, R., Kohn, D., Engelke, D., Rossi, J. J. (1997) The expression cassette determines the functional activity of ribozymes in mammalian cells by controlling their intracellular localization. RNA 3, 75-88.
116. Xing, Z., Whitton, J. L. (1992) Ribozymes which cleave Arenavirus RNAs: Identification of susceptible target sites and inhibition by target site secondary structure. J. Virol. 66, 1361-1369.
117. Kronenwett, R., Haas, R., Sczakiel, G. (1996) Kinetic selectivity of complementary nucleic acids: bcr-abl-directed antisense RNA and ribozymes. J. Mol. Biol. 259, 632-644.
118. Auron, P. E., Rindone, W. P., Vary, C. P. H., Celentano, J. J., Vournakis, J. N. (1982) Computer-aided prediction of RNA secondary structures. Nucleic Acids Res. 11, 403-419.
119. Zhao, J. J., Lemke, G. (1998) Rules for ribozymes. Molec. Cell. Neurosci. 11, 92-97.
120. Jacobson, A. B., Good, L., Simonetti, J., Zuker, M. (1984) Some simple computational methods to improve the folding of large RNAs. Nucleic Acids Res. 12, 45-52.
121. Arndt, G. M., Rank, G. H. (1997) Colocalization of antisense RNAs and ribozymes with their target mRNAs. Genome 40, 785-797.
122. Kim, S. K., Wold, B. J. (1985) Stable reduction of thymidine kinase activity in cells expressing high levels of anti-sense RNA. Cell 42, 129-138.
123. Van der Krol, A. R., Lenting, P. E., Veenstra, J., van der Meer, I. M., Koes, R. E., Gerats, A. G. M., Mol, J. N. M., Stuitje, A. R. (1988) An anti-sense chalcone synthase gene in transgenic plants inhibits flower pigmentation. Nature 333, 866-869.
124. Cannon, M., Platz, J., O'Leary, M., Sookdeo, C., Cannon, F. (1990) Organ-specific modulation of gene expression in transgenic plants using antisense RNA. Plant Mol. Biol. 15, 39-47.
125. Sullenger, B. A., Cech, T. R. (1993) Tethering ribozymes to a retroviral packaging signal for destruction of viral RNA. Science 262, 1566-1569.